Sociedad Argentina de Hematología

Revista Hematología

 

 

 

 

 

Revista Argentina de Hematología

Abstract

Volumen:    19    # Number : Número Extraordinario

Publication Date :    Diciembre    Year:    2015

   ARTÍCULO ORIGINAL

Authors: Drelichman G.; Fernández Escobar N.; Basack N.; Aversa L.; Aguilar G.; Larroudé MS.; Watman N.; Bolesina M.; Kohan R.; Elena G.; Veber SE.; Dragosky M.; Márquez M.; Feliú A.; Sciuccati G.; Cuello MF.; Fynn A.; Aznar M.; Guelbert NB.; Oliveri B.; Schenone AB.; Reichel P.; Ruiz A.; Chain JJ.; Arizo A.; Bietti J.; Barr D.; Zirone S.; Bacciedoni V.; Del Río F.; Cédola A.; Gatto E.; Echeverry J.; Borchichi S.; Schweri M.; Aggio M.; Kisinovsky I.; Fernández V.; Rozenfeld P.; Soberon B.; Lezscano A.; Núñez G.; Baduel C.; Fernández Sasso D.; Diez B.

Abstract: Gaucher disease (GD) is a chronic, progressive and multisystemic disease. The diagnosis of GD must be established by enzyme analysis, acid β-glucosidase (GCase) activity. This determination is essential for diagnosis and relevant before initiating treatment with enzyme replacement therapy (ERT). Bone marrow biopsy (BM) and/or liver biopsy are not necessary for diagnosis purpose, the presence of Gaucher cells may guide to a suspicion but does not replace the need to determine enzyme activity. ERT is the current standard treatment for GD type 1 patients. It has significantly improved the quality of life of these patients. Treatment is lifelong. Marking therapeutic goals (TG) encourages compliance and minimizes treatment interruptions. TG are used to monitor the response to treatment. The achievement of TG is used to evaluate adjustments in the therapeutic regimen. Dosage adjustments should only be considered when the TG have been achieved and maintained. When a TG is lost one must rule out other causes other than treatment failure as: irregular adherence to treatment, inadequate dosing of ERT or the possibility of an associated pathology that could be affecting the monitoring tests. Individualized dose ERT regimen and the follow up with a multidisciplinary team is most efficient and best cost-benefit ratio method to improve the health of patients with GD type 1. This consensus represents the evaluation of current scientific information and will be reviewed and analyzed periodically.

Key words:

Pages :

  Resumen             pdf  

SOCIEDAD ARGENTINA DE HEMATOLOGÍA
Julián Alvarez 146 - Ciudad Autónoma de Bs As - Argentina
(54-11) 4855-2452 / 2485

http://www.sah.org.ar/revista/